New Data from Ciforadenant Phase 1b/2 Clinical Study Presented at ESMO Virtual Congress 2020
September 17, 2020 03:01 ET
|
Corvus Pharmaceuticals, Inc.
Data is part of Genentech’s MORPHEUS umbrella program and covers patients with resistant/refractory NSCLC treated with ciforadenant in combination with atezolizumab Results consistent with prior...
Corvus Pharmaceuticals Appoints Edith Mitchell, M.D., to Board of Directors
September 11, 2020 08:30 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that Edith P. Mitchell, M.D., has been...
Corvus Pharmaceuticals Provides Update on Clinical Trial of CPI-006 for Patients with COVID-19
September 10, 2020 08:30 ET
|
Corvus Pharmaceuticals, Inc.
Characterization of novel immunotherapy approach with CPI-006 and details of COVID-19 clinical trial results submitted for publication online at medRxiv.org Patients treated in first two cohorts of...
Corvus Announces Participation in Upcoming Investor Conferences
September 08, 2020 18:02 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the following...
Corvus Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
August 04, 2020 16:05 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the 2020...
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results
July 30, 2020 16:02 ET
|
Corvus Pharmaceuticals, Inc.
Provides Update on CPI-006 Phase 1 COVID-19 Study Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc....
Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2020 Financial Results on July 30, 2020
July 23, 2020 08:30 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference...
Corvus Pharmaceuticals Initiates Clinical Trial of Novel Immunotherapy for Patients with COVID-19
July 07, 2020 07:00 ET
|
Corvus Pharmaceuticals, Inc.
Approach stimulates immune response by activating B cells to enhance antibody production Safety and scientific basis supported by ongoing cancer clinical trial Study designed to evaluate anti-viral...
Corvus Pharmaceuticals Presents Updated Clinical Data Supporting and Refining the Adenosine Gene Signature’s Ability to Identify Patients Likely to Respond to Treatment with Ciforadenant
May 29, 2020 08:00 ET
|
Corvus Pharmaceuticals, Inc.
Elucidation of CD68 as a Downstream Target of Adenosine Refines Adenosine Gene Signature into a Practical Pathology Test Provides Opportunity to Further Enrich Patient Selection for Responders Data...
Corvus Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare Conference
May 27, 2020 08:00 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of...